Edesa Biotech Stock Net Income
EDSA Stock | USD 4.45 0.33 8.01% |
Edesa Biotech fundamentals help investors to digest information that contributes to Edesa Biotech's financial success or failures. It also enables traders to predict the movement of Edesa Stock. The fundamental analysis module provides a way to measure Edesa Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edesa Biotech stock.
The current year's Net Income Per E B T is expected to grow to 1.10, whereas Net Loss is forecasted to decline to (7.9 M). Edesa | Net Income |
Edesa Net Income Analysis
Edesa Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
More About Net Income | All Equity Analysis
Edesa Biotech Net Income |
|
Net Income | = | (Rev + Gain) | - | (Exp + Loss) |
Current Edesa Biotech Net Income | (8.37 M) |
Most of Edesa Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edesa Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Edesa Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Edesa Biotech reported net income of (8.37 Million). This is 102.45% lower than that of the Biotechnology sector and 111.96% lower than that of the Health Care industry. The net income for all United States stocks is 101.47% higher than that of the company.
Edesa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edesa Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edesa Biotech could also be used in its relative valuation, which is a method of valuing Edesa Biotech by comparing valuation metrics of similar companies.Edesa Biotech is currently under evaluation in net income category among related companies.
Edesa Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Edesa Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Edesa Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Edesa Biotech's value.Shares | Crédit Agricole S.a. | 2023-09-30 | 0.0 | Two Sigma Investments Llc | 2023-09-30 | 0.0 | Dimensional Fund Advisors, Inc. | 2023-09-30 | 0.0 |
Edesa Fundamentals
Return On Equity | -0.96 | ||||
Return On Asset | -0.56 | ||||
Current Valuation | 8.88 M | ||||
Shares Outstanding | 3.17 M | ||||
Shares Owned By Insiders | 18.85 % | ||||
Shares Owned By Institutions | 10.89 % | ||||
Number Of Shares Shorted | 17.73 K | ||||
Price To Earning | (3.96) X | ||||
Price To Book | 2.24 X | ||||
Price To Sales | 120,478 X | ||||
Gross Profit | 311.2 K | ||||
EBITDA | (9.22 M) | ||||
Net Income | (8.37 M) | ||||
Cash And Equivalents | 12.81 M | ||||
Cash Per Share | 0.83 X | ||||
Total Debt | 94.49 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 2.68 X | ||||
Book Value Per Share | 1.85 X | ||||
Cash Flow From Operations | (6.64 M) | ||||
Short Ratio | 0.87 X | ||||
Earnings Per Share | (20.16) X | ||||
Target Price | 24.0 | ||||
Number Of Employees | 16 | ||||
Beta | 0.93 | ||||
Market Capitalization | 13.07 M | ||||
Total Asset | 8.89 M | ||||
Retained Earnings | (52.42 M) | ||||
Working Capital | 4.61 M | ||||
Current Asset | 6.92 M | ||||
Current Liabilities | 581.49 K | ||||
Z Score | 71.93 | ||||
Net Asset | 8.89 M |
About Edesa Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edesa Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edesa Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edesa Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Net Loss | -7.5 M | -7.9 M | |
Net Loss | -15.8 M | -15 M | |
Net Loss | -7.5 M | -7.9 M | |
Net Income Per E B T | 1.00 | 1.10 |
Pair Trading with Edesa Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Edesa Stock
0.65 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
0.41 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.41 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Edesa Biotech Piotroski F Score and Edesa Biotech Altman Z Score analysis. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.56) | Return On Equity (0.96) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.